Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer

被引：0
|
作者：
Schroeder, B. E.
Zhang, Y.
Stal, O.
Fornander, T.
Brufsky, A.
Sgroi, D. C.
Schnabel, C. A.
机构：
[1] Biotheranostics Inc, San Diego, CA USA
[2] Linkoping Univ, Linkoping, Sweden
[3] Karolinska Inst, Stockholm, Sweden
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Massachesetts Gen Hosp, Boston, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-05-14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-05-14
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Chemotherapy use for hormone receptor-positive, node-negative breast cancer
    Hassett, M. J.
    Hughes, M. E.
    Niland, J. C.
    Edge, S. B.
    Theriault, R. L.
    Wong, Y.
    Wilson, J.
    Carter, B. W.
    Blayney, D. W.
    Weeks, J. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer
    Sestak, Ivana
    Zhang, Yi
    Schroeder, Brock E.
    Schnabel, Catherine A.
    Dowsett, Mitch
    Cuzick, Jack
    Sgroi, Dennis
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5043 - 5048
  • [3] Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
    Schroeder, Brock
    Zhang, Yi
    Stal, Olle
    Fornander, Tommy
    Brufsky, Adam
    Sgroi, Dennis C.
    Schnabel, Catherine A.
    [J]. NPJ BREAST CANCER, 2017, 3
  • [4] Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
    Brock Schroeder
    Yi Zhang
    Olle Stål
    Tommy Fornander
    Adam Brufsky
    Dennis C. Sgroi
    Catherine A. Schnabel
    [J]. npj Breast Cancer, 3
  • [5] Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
    Hassett, Michael J.
    Hughes, Melissa E.
    Niland, Joyce C.
    Edge, Stephen B.
    Theriault, Richard L.
    Wong, Yu-Ning
    Wilson, John
    Carter, W. Bradford
    Blayney, Douglas W.
    Weeks, Jane C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5553 - 5560
  • [6] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    [J]. HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [7] Health economic impact of breast cancer index (BCI) for late disease management in patients with estrogen receptor-positive, node-negative breast cancer
    Gustavsen, G.
    Schroeder, B. E.
    Kennedy, P.
    Pothier, K.
    Erlander, M. G.
    Schnabel, C. A.
    [J]. CANCER RESEARCH, 2013, 73
  • [8] Conversion to node-negative after neoadjuvant chemotherapy is a surrogate prognostic marker in patients with hormone receptor-positive breast cancer
    Takahashi, Y.
    Hayashi, N.
    Matsuda, N.
    Kajiura, Y.
    Yoshida, A.
    Yagata, H.
    Nakamura, S.
    Suzuki, K.
    Tsunoda, H.
    Yamauchi, H.
    [J]. CANCER RESEARCH, 2013, 73
  • [9] A risk index for early node-negative breast cancer
    Boyages, J.
    Taylor, R.
    Chua, B.
    Ung, O.
    Bilous, M.
    Salisbury, E.
    Wilcken, N.
    [J]. BRITISH JOURNAL OF SURGERY, 2006, 93 (05) : 564 - 571
  • [10] Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer
    Panasci, LC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2392 - 2392
12345